Joseph Cafone1, Melanie A Ruffner1,2, Jonathan M Spergel3,4. 1. Department of Pediatrics, Division of Allergy and Immunology, Children's Hospital of Philadelphia, Wood Building, 3rd floor, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. 2. Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Pediatrics, Division of Allergy and Immunology, Children's Hospital of Philadelphia, Wood Building, 3rd floor, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. spergel@email.chop.edu. 4. Institute for Immunology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. spergel@email.chop.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to provide a brief discussion on the differential diagnosis for peripheral eosinophilia. We will then focus on targeted immunotherapies for atopic disease, their effects on absolute peripheral eosinophil counts, and use of peripheral eosinophils as a predictor of treatment response. RECENT FINDINGS: In atopic disease, lower absolute peripheral eosinophil counts are typically associated with improved outcomes. Much of the current evidence on eosinophils as a biomarker comes from post hoc analyses in therapeutic immunotherapy. While changes in eosinophilia were not the primary outcome of interest in many studies, some patterns did emerge. Cytolytic monoclonal antibodies AK002 and benralizumab completely reduce peripheral and tissue eosinophil numbers. Dupilumab may have paradoxical transient eosinophilia despite observed clinical efficacy. Atopic inflammation is complex largely due to the various cytokines which affect eosinophil activation, proliferation, differentiation, and survival. This demonstrates the challenges of using peripheral eosinophilia alone as a biomarker for atopic disease activity. More attention should spotlight how different immunotherapy modalities affect eosinophil-driven responses.
PURPOSE OF REVIEW: The purpose of this review is to provide a brief discussion on the differential diagnosis for peripheral eosinophilia. We will then focus on targeted immunotherapies for atopic disease, their effects on absolute peripheral eosinophil counts, and use of peripheral eosinophils as a predictor of treatment response. RECENT FINDINGS: In atopic disease, lower absolute peripheral eosinophil counts are typically associated with improved outcomes. Much of the current evidence on eosinophils as a biomarker comes from post hoc analyses in therapeutic immunotherapy. While changes in eosinophilia were not the primary outcome of interest in many studies, some patterns did emerge. Cytolytic monoclonal antibodies AK002 and benralizumab completely reduce peripheral and tissue eosinophil numbers. Dupilumab may have paradoxical transient eosinophilia despite observed clinical efficacy. Atopic inflammation is complex largely due to the various cytokines which affect eosinophil activation, proliferation, differentiation, and survival. This demonstrates the challenges of using peripheral eosinophilia alone as a biomarker for atopic disease activity. More attention should spotlight how different immunotherapy modalities affect eosinophil-driven responses.
Authors: Jonathan M Spergel; Marc E Rothenberg; Margaret H Collins; Glenn T Furuta; Jonathan E Markowitz; George Fuchs; Molly A O'Gorman; Juan Pablo Abonia; James Young; Timothy Henkel; H Jeffrey Wilkins; Chris A Liacouras Journal: J Allergy Clin Immunol Date: 2011-12-28 Impact factor: 10.793
Authors: P G Woodruff; R Khashayar; S C Lazarus; S Janson; P Avila; H A Boushey; M Segal; J V Fahy Journal: J Allergy Clin Immunol Date: 2001-11 Impact factor: 10.793
Authors: Jonathan M Spergel; Evan S Dellon; Chris A Liacouras; Ikuo Hirano; Javier Molina-Infante; Albert J Bredenoord; Glenn T Furuta Journal: Ann Allergy Asthma Immunol Date: 2018-07-18 Impact factor: 6.347
Authors: Eric L Simpson; Thomas Bieber; Emma Guttman-Yassky; Lisa A Beck; Andrew Blauvelt; Michael J Cork; Jonathan I Silverberg; Mette Deleuran; Yoko Kataoka; Jean-Philippe Lacour; Külli Kingo; Margitta Worm; Yves Poulin; Andreas Wollenberg; Yuhwen Soo; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; Heribert Staudinger; Vera Mastey; Laurent Eckert; Abhijit Gadkari; Neil Stahl; George D Yancopoulos; Marius Ardeleanu Journal: N Engl J Med Date: 2016-09-30 Impact factor: 91.245
Authors: Sumita Khatri; Wendy Moore; Peter G Gibson; Richard Leigh; Arnaud Bourdin; Jorge Maspero; Manuel Barros; Roland Buhl; Peter Howarth; Frank C Albers; Eric S Bradford; Martyn Gilson; Robert G Price; Steven W Yancey; Hector Ortega Journal: J Allergy Clin Immunol Date: 2018-10-23 Impact factor: 10.793
Authors: Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich Journal: N Engl J Med Date: 2008-03-16 Impact factor: 91.245
Authors: Christopher E Brightling; Pascal Chanez; Richard Leigh; Paul M O'Byrne; Stephanie Korn; Dewei She; Richard D May; Katie Streicher; Koustubh Ranade; Edward Piper Journal: Lancet Respir Med Date: 2015-07-28 Impact factor: 30.700
Authors: Rania Dagher; Varsha Kumar; Alan M Copenhaver; Sandra Gallagher; Mahboobe Ghaedi; Jonathan Boyd; Paul Newbold; Alison A Humbles; Roland Kolbeck Journal: Eur Respir J Date: 2022-03-03 Impact factor: 16.671